. 2022 Nov 29;13:7086. doi: 10.1038/s41467-022-34616-8

Table 2.

Sex and age- adjusted prevalence and prevalence difference of persistent symptoms

Age group (years)	Serological status	Prevalence of symptoms lasting over 12 weeks Percent^a,b,c (95%CI)	Prevalence difference of symptoms lasting over 12 weeks Percent^a,b,c (95%CI)
Female (n = 528)^d
	Negative	4.9 (2.2;7.6)
	Positive	8.3 (4.9;11.6)
	Difference		3.4 (−1.1;8.4)
Male (n = 505)^d
	Negative	5.0 (2.12;8.0)
	Positive	9.7 (6.4;13.2)
	Difference		4.7 (0.2;9.4)
0–5 (n = 160)
	Negative	3.8 (0.0;8.1)
	Positive	8.0 (1.8;14.2)
	Difference		4.2 (−4.4;13.3)
6–11 (n = 445)
	Negative	5.3 (2.0;8.6)
	Positive	5.3 (2.6;8.1)
	Difference		0.0 (−5.2;5.2)
12–17 (n = 429)
	Negative	5.3 (2.3;8.4)
	Positive	13.6 (9.3;18.1)
	Difference		8.3 (3.5;13.5)
All ages (n = 1034)
	Negative	5.0 (3.0;7.1)
	Positive	9.1 (6.7;11.8)
	Difference		4.1 (1.1;7.3)

^aAdjusted for age and sex, when appropriate.

^bA model additionally adjusting for chronic condition, financial situation and parental education yielded similar results.

^cUnadjusted estimates are presented in Table S5.

^dAs presented in Table 1, one child had no biological sex assigned.